| 43.8 0.26 (0.6%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 54.33 | 1-year : | 56.74 |
| Resists | First : | 46.52 | Second : | 48.58 |
| Pivot price | 44.65  |
|||
| Supports | First : | 43.18 | Second : | 35.93 |
| MAs | MA(5) : | 44.1 |
MA(20) : | 44.82 |
| MA(100) : | 46.81 |
MA(250) : | 52.09 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 10.6 |
D(3) : | 16.3 |
| RSI | RSI(14): 39.8  |
|||
| 52-week | High : | 63.33 | Low : | 42.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMY ] has closed above bottom band by 28.4%. Bollinger Bands are 0.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 43.96 - 44.21 | 44.21 - 44.43 |
| Low: | 42.62 - 42.94 | 42.94 - 43.24 |
| Close: | 43.33 - 43.8 | 43.8 - 44.23 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Tue, 14 Oct 2025
BMY Collaboration Advances ALS Treatment Development - GuruFocus
Tue, 14 Oct 2025
$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan
Tue, 14 Oct 2025
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Tue, 14 Oct 2025
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - Yahoo Finance
Mon, 13 Oct 2025
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,040 (M) |
| Shares Float | 2,030 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 84.6 (%) |
| Shares Short | 26,340 (K) |
| Shares Short P.Month | 31,190 (K) |
| EPS | 2.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.56 |
| Profit Margin | 10.5 % |
| Operating Margin | 33.6 % |
| Return on Assets (ttm) | 8.3 % |
| Return on Equity (ttm) | 29.3 % |
| Qtrly Rev. Growth | 0.6 % |
| Gross Profit (p.s.) | 17.28 |
| Sales Per Share | 23.38 |
| EBITDA (p.s.) | 9.36 |
| Qtrly Earnings Growth | -22.8 % |
| Operating Cash Flow | 15,900 (M) |
| Levered Free Cash Flow | 16,190 (M) |
| PE Ratio | 17.59 |
| PEG Ratio | 0 |
| Price to Book value | 5.11 |
| Price to Sales | 1.87 |
| Price to Cash Flow | 5.61 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 1.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|